Orchid Pharma
Ticker > Company >

Orchid Pharma share price

Orchid Pharma Ltd.

NSE: ORCHPHARMA BSE: 524372 SECTOR: Pharmaceuticals & Drugs  44k   97   7

1790.65
-39.25 (-2.14%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 1841.1

Today's Low

₹ 1770.6

52 Week High

₹ 1841.1

52 Week Low

₹ 692.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 9082.02 Cr.

Enterprise Value

₹ 8959.05 Cr.

No. of Shares

5.07 Cr.

P/E

76.67

P/B

7.14

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  250.68

CASH

₹ 257.23 Cr.

DEBT

₹ 134.26 Cr.

Promoter Holding

69.84 %

EPS (TTM)

₹  23.36

Sales Growth

23.05%

ROE

9.72 %

ROCE

8.96%

Profit Growth

71.5 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year23.05%
3 Year22.05%
5 Year7.02%

Profit Growth

1 Year74.85%
3 Year41.09%
5 Year24.05%

ROE%

1 Year9.72%
3 Year3.26%
5 Year-83.24%

ROCE %

1 Year8.96%
3 Year5.29%
5 Year1.62%

Debt/Equity

0.1102

Price to Cash Flow

69.47

Interest Cover Ratio

6.4776

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 69.84 0.00
Jun 2024 69.84 0.00
Mar 2024 69.84 0.00
Dec 2023 69.84 0.00
Sep 2023 72.40 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 44.0370535255476% for the Past 3 years.
  • The company has shown a good revenue growth of 22.0481655906603% for the Past 3 years.
  • The company has significantly decreased its debt by 197.0891 Cr.
  • The company has an efficient Cash Conversion Cycle of 82.9641 days.
  • Company has a healthy liquidity position with current ratio of 3.731.
  • The company has a high promoter holding of 69.84%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 10.6013351584386.

 Limitations

  • Company has a poor ROE of 3.26299671822645% over the past 3 years.
  • Tax rate is low at -3.525.
  • The company is trading at a high PE of 76.67.
  • The company is trading at a high EV/EBITDA of 55.0449.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 198.76 220.59 217.1 244.41 222.7
Total Expenditure 175.06 184.68 188.18 211.16 193.11
Operating Profit 23.7 35.92 28.93 33.25 29.59
Other Income 8.18 7.44 12.89 7.77 7.96
Interest 3.8 3.54 3.45 3.47 3.3
Depreciation 7.84 9.27 8.4 8.44 8.63
Exceptional Items 0 0 0 0 0
Profit Before Tax 20.24 30.55 29.96 29.1 25.63
Tax 0 0 -3.23 0 0
Profit After Tax 20.24 30.55 33.19 29.1 25.63
Adjusted EPS (Rs) 3.99 6.02 6.54 5.74 5.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 481.21 450.7 556.97 665.9 819.37
Total Expenditure 469.81 391.92 498.27 581.6 708.57
Operating Profit 11.4 58.77 58.7 84.29 110.8
Other Income 24.28 6.46 9 19.43 30.65
Interest 6.22 52.21 33.46 32.9 16.71
Depreciation 117.91 108.9 87.02 54.79 33.22
Exceptional Items 0 0 0 39.21 0
Profit Before Tax -88.46 -95.87 -52.77 55.25 91.52
Tax 0 0 0 0 -3.23
Net Profit -149.84 -117.15 -4.81 54.19 94.75
Adjusted EPS (Rs.) -21.67 -23.49 -12.93 13.54 18.68

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 40.82 40.82 40.82 40.82 50.72
Total Reserves 757.01 640.52 637.14 691.15 1167.6
Borrowings 503.97 427.5 208.17 148.84 120.21
Other N/C liabilities 15.01 14.77 14.24 15.83 4
Current liabilities 133.18 100.87 193.83 326.63 209.67
Total Liabilities 1449.99 1224.47 1094.19 1223.26 1552.2
Assets
Net Block 857.86 670.39 583.65 573.06 616.43
Capital WIP 15.07 7.43 9.78 46.09 10.18
Intangible WIP 10.54 0 0 0 14.28
Investments 0.34 0.4 49.01 50.12 69.4
Loans & Advances 1.41 3.98 68.66 60.2 59.61
Other N/C Assets 0 120.87 13.3 0 0.02
Current Assets 564.77 421.4 369.78 493.79 782.29
Total Assets 1449.99 1224.47 1094.19 1223.26 1552.2
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -149.84 -117.15 -4.81 54.19 91.52
Adjustment 174.58 163.69 38.24 54.1 41.68
Changes in Assets & Liabilities 45.25 -27.1 58.04 -94.6 -3.22
Tax Paid 10.42 4.92 -1.91 -0.3 0.74
Operating Cash Flow 80.42 24.36 89.57 13.39 130.73
Investing Cash Flow 167.12 67.21 112.93 -26.7 -315.81
Financing Cash Flow -250.33 -164.99 -216.8 31.17 167.07
Net Cash Flow -2.79 -73.42 -14.3 17.86 -18.01

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 72.40 69.84 69.84 69.84 69.84
dhanuka laboratories limi... 72.40 69.84 69.84 69.84 69.84
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 27.60 30.16 30.16 30.16 30.16
invesco india equity savi... - - - - 4.84
jm financial mutual fund-... - - - - 1.15
nippon life india trustee... 1.97 - 1.43 1.43 1.23
quant mutual fund - quant... - 3.03 - 6.83 6.83
invesco india esg integra... - - - 4.98 -
jm financial mutual fund ... - - - 1.10 -
carnelian structural shif... 1.22 1.22 1.22 - -
invesco india contra fund... - - 3.97 - -
quant mutual fund-quant v... - - 6.83 - -
massachusetts institute o... 4.64 2.91 - - -
max life insurance compan... - 2.44 - - -
nippon life india trustee... - 1.69 - - -
quant mutual fund quant... 2.49 2.49 - - -
quant mutual fund quant v... - 1.32 - - -
uti - healthcare fund - 1.08 - - -
238 plan associates llc 1.22 - - - -
quant mutual fund quant... 2.56 - - - -
quant mutual fund quant... 1.32 - - - -
societe generale 1.57 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Orchid Pharma informs about newspaper publication 12 Nov, 4:58 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 12 Aug, 7:29 PM Orchid Pharma - Quaterly Results 12 Aug, 7:29 PM Orchid Pharma submits analyst meet intimation 7 Aug, 5:07 PM Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India 28 Jun, 4:14 PM Orchid Pharma gets DCGI’s approval for Antibiotic Drug Combination of Cefepime and Enmetazobactam 6 Jun, 12:40 PM Orchid Pharma informs about investor roadshow 4 Jun, 2:43 PM Orchid Pharma - Quaterly Results 23 May, 8:17 PM Orchid Pharma - Quaterly Results 23 May, 8:17 PM Orchid Pharma informs about analyst meet 17 May, 5:33 PM Orchid Pharma informs about outcome of board meeting 8 Feb, 5:16 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma informs about disclosure 31 Jan, 4:51 PM Orchid Pharma informs about disclosures 27 Dec, 11:30 AM Orchid Pharma informs about disclosures 26 Dec, 2:35 PM Orchid Pharma informs about disclosure 26 Dec, 12:23 PM Orchid Pharma informs about disclosure 22 Dec, 4:34 PM Orchid Pharma informs about revision of credit rating 15 Dec, 4:57 PM Orchid Pharma informs about resignation of CS cum CO 14 Dec, 3:23 PM Orchid Pharma informs about disclosures 29 Nov, 5:18 PM Orchid Pharma - Quaterly Results 4 Nov, 6:58 PM Orchid Pharma - Quaterly Results 4 Nov, 6:58 PM Orchid Pharma informs about newspaper advertisements 28 Oct, 3:38 PM Orchid Pharma inks manufacturing sublicense agreement with GARDP 12 Sep, 4:47 PM Orchid Pharma submits monitoring agency report 14 Aug, 1:39 PM Orchid Pharma - Quaterly Results 10 Aug, 7:18 PM Orchid Pharma - Quaterly Results 10 Aug, 7:18 PM Orchid Pharma informs about conference call 8 Aug, 5:24 PM Orchid Pharma - Quaterly Results 10 May, 10:11 PM Orchid Pharma - Quaterly Results 10 May, 10:11 PM Orchid Pharma informs about certificate 12 Apr, 4:30 PM Orchid Pharma’s arm inks MoU with overseas technology provider 4 Mar, 5:23 PM Orchid Pharma informs about disclosure 4 Mar, 12:09 PM Orchid Pharma informs about transcript of investor call 22 Feb, 5:02 PM Orchid Pharma - Quaterly Results 9 Feb, 6:34 PM Orchid Pharma - Quaterly Results 9 Feb, 6:34 PM Orchid Pharma informs about analyst meet 15 Dec, 4:24 PM Orchid Pharma gets board’s nod to raise Rs 500 crore through QIP 2 Dec, 2:10 PM Orchid Pharma informs about board meeting 1 Dec, 4:13 PM Orchid Pharma - Quaterly Results 14 Nov, 5:33 PM Orchid Pharma - Quaterly Results 14 Nov, 5:33 PM Orchid Pharma - Quaterly Results 10 Aug, 4:29 PM Orchid Pharma - Quaterly Results 10 Aug, 4:29 PM Orchid Pharma’s arm gets nod to manufacture product ‘7 ACA’ with committed capacity 18 Jul, 12:17 PM Orchid Pharma informs about proceedings of AGM 16 Jul, 3:37 PM

Orchid Pharma Stock Price Analysis and Quick Research Report. Is Orchid Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Orchid Pharma and its performance over the period of time. Orchid Pharma stock price today is Rs 1790.65.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Orchid Pharma cash from the operating activity was Rs 130.7258 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Orchid Pharma has a Debt to Equity ratio of 0.1102 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Orchid Pharma , the EPS growth was 38.0163 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Orchid Pharma has OPM of 13.5221747683154 % which is a bad sign for profitability.
     
  • ROE: Orchid Pharma have a poor ROE of 9.7165 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Orchid Pharma is Rs 1790.65. One can use valuation calculators of ticker to know if Orchid Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Orchid Pharma

Orchid Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Orchid Pharma Ltd. is a pharmaceutical company based in Chennai, India. Founded in 1992, the company focuses on research, development, manufacture, and marketing of active pharmaceutical ingredients and formulations. Orchid Pharma has a strong presence in over 35 therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, anti-infectives, and much more. The company has several manufacturing facilities in India and is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Orchid Pharma Ltd. - Share Price

The share price of Orchid Pharma Ltd. is updated in real-time on our stock analysis page. Investors can track the movement of the share price for the day and other relevant information such as the opening price, closing price, high and low of the day, and the volume traded. We also offer interactive charts that display the historical prices and movements of the stock.

Orchid Pharma Ltd. - Balance Sheet

A company's balance sheet reflects its financial health and provides insights into its assets, liabilities, and equity. Orchid Pharma Ltd.'s balance sheet can be accessed from our website as a downloadable document. We also offer our premium tool, the DuPont analysis, that allows investors to calculate the company's financial leverage, operational efficiency, and profitability.

Orchid Pharma Ltd. - Annual Report

The annual report is a comprehensive document that provides an overview of a company's financial performance over the year. Orchid Pharma Ltd.'s annual report can be easily accessed from our website as a downloadable document. Investors can use our pre-built screening tools and their own analysis to identify important information such as revenue growth, profit margins, and the company's financial standing.

Orchid Pharma Ltd. - Dividend

Dividends are a percentage of a company's profits that are paid out to its shareholders. Orchid Pharma Ltd.'s dividend information can be accessed from our stock analysis page. Investors can track the company's dividend yield, payout ratio, and other relevant information such as the ex-dividend date and dividend history.

Orchid Pharma Ltd. - Quarterly Result

The quarterly result provides an overview of a company's financial performance over the preceding three months. Orchid Pharma Ltd.'s quarterly results can be easily accessed from our website. We also offer our premium tools such as the DCF analysis and the earnings multiple approach that allow investors to determine the fair value of the company's stock based on key financial ratios and projections.

Orchid Pharma Ltd. - Stock Price

The stock price of Orchid Pharma Ltd. can be tracked in real-time on our stock analysis page. Investors can access the interactive price chart that displays the historical prices and movements of the stock over time. We also provide news updates and market analysis to keep investors informed about the latest developments in the pharmaceutical industry.

Orchid Pharma Ltd. - Price Chart

Investors can access the interactive price chart of Orchid Pharma Ltd.'s stock on our stock analysis page. The chart allows investors to view the historical prices and movements of the stock over time. Our premium tools such as the BVPS analysis and the DCF analysis allow investors to determine the intrinsic value of the company's stock and make informed investment decisions.

Orchid Pharma Ltd. - News

Our stock analysis page provides investors with timely and relevant news updates about Orchid Pharma Ltd. and the pharmaceutical industry. Our news feed includes updates on the company's financial performance, regulatory changes, mergers and acquisitions, and other market developments. Investors can use these updates to make informed investment decisions and stay ahead of the curve.

Orchid Pharma Ltd. - Concall Transcripts

Investors can access Orchid Pharma Ltd.'s concall transcripts on our website as a downloadable document. The transcripts provide a summary of the company's financial performance over the preceding quarter along with insights from the management team. Investors can use these transcripts to gain a deeper understanding of the company's prospects and make informed investment decisions.

Orchid Pharma Ltd. - Investor Presentations

Orchid Pharma Ltd.'s investor presentations can be accessed from our website as a downloadable document. The presentations provide investors with an overview of the company's business model, financial performance, and market prospects. Investors can use these presentations to stay informed about the latest developments at the company and make informed investment decisions.

Orchid Pharma Ltd. - Promoters

Orchid Pharma Ltd.'s promoters are a key driver in the company's success. Our stock analysis page features information about the company's promoters, their key traits, and their contributions to the company's growth. This information can help investors gain insights into the company's management team and make informed investment decisions.

Orchid Pharma Ltd. - Shareholders

Orchid Pharma Ltd.'s shareholders are an important stakeholder group that can impact the company's performance. Our stock analysis page features information about the company's major shareholders, their voting patterns, and their contributions to the company. This information can help investors understand the company's shareholder structure and make informed investment decisions.

In conclusion, Orchid Pharma Ltd. is a reputable pharmaceutical company listed on the NSE and BSE stock exchanges. Our website provides investors with timely and relevant information about the company's financial performance, share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news updates, concall transcripts, investor presentations, promoters, and shareholders. We also offer pre-built screening tools and premium features such as the DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis that can help investors make informed investment decisions.

Read More
X